Scholar Rock Holding Corporation’s SRRK share price has dipped by 5.79%, which has investors questioning if this is right ...

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases ...

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s shares opened today at $32.56. Discover outperforming stocks ...

Scholar Rock Stock Down 1.6 % Shares of NASDAQ SRRK opened at $32.84 on Friday. The stock has a market capitalization of $3.11 billion, a P/E ratio of -13.97 and a beta of 0.59. Scholar Rock ...

1 Day SRRK 2.78% DJIA 1.07% S&P Mid Cap 400 1.34% Health Care/Life Sciences -1.43% ...

Pundit Allison Bratzel is quite bullish on its leading drug candidate. Scholar Rock targets relatively uncommon disorders that might lack effective treatments. Its current lead drug candidate ...

Scholar Rock targets relatively uncommon disorders that might lack effective treatments. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks ...

Its current lead drug candidate -- apitegromab, a medicine that preserves muscle mass in patients with two types of spinal muscular atrophy (SMA) -- is under review for approval by both the U.S ...